Sonies BC, Ekman EF, Andersson HC, Adamson MD, Kaler SG, Markello TC, Gahl WA (1990) Swallowing dysfunction in nephropathic cystinosis
However, the specific metabolic checkpoints of the altered thresholds need further exploration, which is a future research direction
ClinicalTrials+1 Classified as prohibited by anti-doping authorities (USADA/WADA) and noted by other regulators (e.g., TGA) as an unapproved growth-factor peptide
Currently used antidepressant drugs, which mostly target brain monoaminergic neurotransmission, have limited clinical efficacy
MMRi62 may be particularly effective in treating PDAC patients with TP53 mutations [105]
In vitro and in vivo lipolysis To assess the role of GPR146 in lipolysis, both in vitro and in vivo assays were performed